Hilgers, Reinhard

[["dc.bibliographiccitation.artnumber","R129"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","CRITICAL CARE"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Waeschle, Reiner M."],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Herrmann, Peter"],["dc.contributor.author","Neumann, Peter"],["dc.contributor.author","Quintel, Michael"],["dc.date.accessioned","2018-11-07T11:19:45Z"],["dc.date.available","2018-11-07T11:19:45Z"],["dc.date.issued","2008"],["dc.description.abstract","Introduction The purpose of this study was to assess the relation between glycaemic control and the severity of sepsis in a cohort of patients treated with intensive insulin therapy (IIT). Methods In a prospective, observational study, all patients in the intensive care unit (ICU) (n = 191) with sepsis, severe sepsis or septic shock were treated with IIT (target blood glucose (BG) level 80 to 140 mg/dl instead of strict normoglycaemia). BG values were analysed by calculating mean values, rate of BG values within different ranges, rate of patients experiencing BG values within different levels and standard deviation (SD) of BG values as an index of glycaemic variability. Results The number of patients with hypoglycaemia and hyperglycaemia was highly dependent on the severity of sepsis (critical hypoglycaemia <= 40 mg/dl: sepsis: 2.1%, severe sepsis: 6.0%, septic shock: 11.5%, p = 0.1497; hyperglycaemia: > 140 mg/dl: sepsis: 76.6%, severe sepsis: 88.0%, septic shock: 100%, p = 0.0006; > 179 mg/dl: sepsis: 55.3%, severe sepsis: 73.5%, septic shock: 88.5%, p = 0.0005; > 240 mg/dl: sepsis: 17.0%, severe sepsis: 48.2%, septic shock: 45.9%, p = 0.0011). Multivariate analyses showed a significant association of SD levels with critical hypoglycaemia especially for patients in septic shock (p = 0.0197). In addition, SD levels above 20 mg/dl were associated with a significantly higher mortality rate relative to those with SD levels below 20 mg/dl (24% versus 2.5%, p = 0.0195). Conclusions Patients with severe sepsis and septic shock who were given IIT had a high risk of hypoglycaemia and hyperglycaemia. Among these patients even with a higher target BG level, IIT mandates an increased awareness of the occurrence of critical hypoglycaemia, which is related to the severity of the septic episode."],["dc.identifier.doi","10.1186/cc7097"],["dc.identifier.isi","000261561100017"],["dc.identifier.pmid","18939991"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4949"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55364"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1466-609X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","199"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Annals of Neurology"],["dc.bibliographiccitation.lastpage","210"],["dc.bibliographiccitation.volume","72"],["dc.contributor.author","Sühs, K.-W."],["dc.contributor.author","Hein, K."],["dc.contributor.author","Sättler, M. B."],["dc.contributor.author","Görlitz, A."],["dc.contributor.author","Ciupka, C."],["dc.contributor.author","Scholz, K."],["dc.contributor.author","Käsmann-Kellner, B."],["dc.contributor.author","Papanagiotou, P."],["dc.contributor.author","Schäffler, N."],["dc.contributor.author","Restemeyer, C."],["dc.contributor.author","Bittersohl, D."],["dc.contributor.author","Hassenstein, A."],["dc.contributor.author","Seitz, B."],["dc.contributor.author","Reith, W."],["dc.contributor.author","Fassbender, K."],["dc.contributor.author","Hilgers, R."],["dc.contributor.author","Heesen, C."],["dc.contributor.author","Bähr, M."],["dc.contributor.author","Diem, R."],["dc.date.accessioned","2017-09-07T11:48:29Z"],["dc.date.available","2017-09-07T11:48:29Z"],["dc.date.issued","2012"],["dc.description.abstract","Objective: Based on findings in animal models of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of optic neuritis. Methods: Patients with optic neuritis who attended the University Hospitals of Homburg/Saar, Gottingen, or Hamburg (Germany) were included in this double-blind, placebo-controlled, phase 2 study (ClinicalTrials.gov, NCT00355095). They were randomly assigned to groups receiving either 33,000IU recombinant human erythropoietin intravenously daily for 3 days or placebo as an add-on therapy to methylprednisolone. The primary outcome parameter was change in retinal nerve fiber layer (RNFL) thickness after 16 weeks. Secondary outcome parameters included optic nerve atrophy as assessed by magnetic resonance imaging, and changes in visual acuity, visual field, and visual evoked potentials (VEPs). Results: Forty patients were assigned to the treatment groups (21/19 erythropoietin/placebo). Safety monitoring revealed no relevant issues. Thirty-seven patients (20/17 erythropoietin/placebo) were analyzed for the primary endpoint according to the intention-to-treat protocol. RNFL thinning was less apparent after erythropoietin treatment. Thickness of the RNFL decreased by a median of 7.5 mu m by week 16 (mean +/- standard deviation, 10.55 +/- 17.54 mu m) compared to a median of 16.0 mu m (22.65 +/- 29.18 mu m) in the placebo group (p = 0.0357). Decrease in retrobulbar diameter of the optic nerve was smaller in the erythropoietin group (p = 0.0112). VEP latencies at week 16 were shorter in erythropoietin-treated patients than in the placebo group (p = 0.0011). Testing of visual functions revealed trends toward an improved outcome after erythropoietin treatment. Interpretation: These results give the first indications that erythropoietin might be neuroprotective in optic neuritis. ANN NEUROL 2012;72:199210."],["dc.identifier.doi","10.1002/ana.23573"],["dc.identifier.gro","3142489"],["dc.identifier.isi","000307946000010"],["dc.identifier.pmid","22926853"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8846"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0364-5134"],["dc.title","A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","741"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Neurourology and Urodynamics"],["dc.bibliographiccitation.lastpage","746"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Kuszka, Andrzej"],["dc.contributor.author","Rautenberg, Oliver"],["dc.contributor.author","Wlazlak, Edyta"],["dc.contributor.author","Surkont, Grzegorz"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Eberhard, Jakob"],["dc.contributor.author","Kociszewski, Jacek"],["dc.date.accessioned","2018-11-07T09:49:53Z"],["dc.date.available","2018-11-07T09:49:53Z"],["dc.date.issued","2015"],["dc.description.abstract","AimDespite a wide array of vaginal tapes to treat stress urinary incontinence (SUI), evidence suggesting that both patient characteristics and tape positioning influence outcomes, and differing tape insertion pathways (retropubic vs. transobturator), it remains unclear if the same incision location is effective for all tapes. The aim of the study was to compare outcomes using two different surgical incision locations when inserting a transobturator vaginal tape (TOT) to treat SUI. MethodsWe compared patient characteristics, tape positioning, and surgical outcomes in 123 women undergoing a TOT procedure who were randomly assigned to have the surgical incision begin at 1/3 of the sonographically-measured urethral length (similar to the traditional retropubic approach) or 1/2 of the urethral length. ResultsIt was feasible to place the tape according to intention in 99.2% of the study cohort. The overall cure rate was higher when the incision site began at 1/2 the urethral length (83.6%) than 1/3 (62.9%) (P=0.01). In the subgroup analyses, only patients with normal urethral mobility had significantly different cure rates (85.7% vs. 55.2%, P=0.02). No significant differences in cure rates were observed between the other mobility categories of the study groupshypermobility was consistently associated with high cure rates and hypomobility with low cure rates. ConclusionsWhen surgically treating SUI with a TOT, incision at the mid-urethra using the 1/2 rule is recommended as it leads to better outcomes for most patients, particularly those with normal urethral mobility. Neurourol. Urodynam. 34:741-746, 2015. (c) 2014 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/nau.22658"],["dc.identifier.isi","000362963200007"],["dc.identifier.pmid","25176293"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35591"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1520-6777"],["dc.relation.issn","0733-2467"],["dc.title","Do different vaginal tapes need different suburethral incisions? The one-half rule"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","201"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","International Archives of Occupational and Environmental Health"],["dc.bibliographiccitation.lastpage","208"],["dc.bibliographiccitation.volume","81"],["dc.contributor.author","Heutelbeck, Astrid R. R."],["dc.contributor.author","Janicke, Nico"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Kutting, Birgitta"],["dc.contributor.author","Drexler, Hans G."],["dc.contributor.author","Hallier, Ernst"],["dc.contributor.author","Bickeboeller, Heike"],["dc.date.accessioned","2018-11-07T10:57:06Z"],["dc.date.available","2018-11-07T10:57:06Z"],["dc.date.issued","2007"],["dc.description.abstract","Introduction Allergic reactions caused by animals are a common and significant occupational health concern. In a large population-based study on occupational asthma in Europe, farming has been among the occupations with the highest risk. Objectives Characteristics of cattle-allergic farmers are described in a retrospective observational design. Methods The study covers farmers from all regions of Germany which were reported to the Agricultural Institutions for Statutory Accident Insurance and Prevention (Landwirtschaftliche Berufsgenossenschaften, LBGs) between 1990 (January) and 2002 (December) with a suspected occupational cattle-allergic airways disease. For these farmers, the following parameters were considered: age, gender, onset of airways symptoms related to contact with cattle, begin of employment disability, total and specific Immunoglobulin E (IgE) against cattle allergens, and results of lung function measurements. Results A total of 513 patients (age 14-74, mean 40.7 years; 45.6% women, 54.4% men) had been reported for a suspected occupational cattle-allergic airways disease. Of these patients 24.8% showed cattle-related symptoms of asthma, 11.7% of rhinitis, and 60% of both asthma and rhinitis, while only 34.5% of all reported patients showed an airways obstruction in the first documented lung function test. A total of 62.5% out of the group of patients with an officially recognized occupational disease (42.1%, n = 216) have an initial employment disability with a rating of 20% or above. Conclusions Our results underline the high public health relevance of cattle allergy in farmers, especially in the light of the large number of young patients. Considering the known difficulties in diagnosing cattle allergy due to the number of false negative test results, we are convinced that its relevance is even higher than the number of reported cases suggests. The high rate of initial employment disability among the affected patients underlines the need for improved preventive measures."],["dc.identifier.doi","10.1007/s00420-007-0207-y"],["dc.identifier.isi","000250206000008"],["dc.identifier.pmid","17636318"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50165"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-0131"],["dc.title","German cattle allergy study (CAS): public health relevance of cattle-allergic farmers"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","46"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","The American Journal of Cardiology"],["dc.bibliographiccitation.lastpage","52"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Scholz, Karl Heinrich"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Ahlersmann, Dorothe"],["dc.contributor.author","Duwald, Holger"],["dc.contributor.author","Nitsche, Rolf"],["dc.contributor.author","von Knobelsdorff, Georg"],["dc.contributor.author","Volger, Berthold"],["dc.contributor.author","Moeller, Karsten"],["dc.contributor.author","Keating, Friederike K."],["dc.date.accessioned","2018-11-07T11:19:17Z"],["dc.date.available","2018-11-07T11:19:17Z"],["dc.date.issued","2008"],["dc.description.abstract","For many patients with ST-segment elevation myocardial infarctions (STEMIs), the time from presentation to percutaneous coronary intervention exceeds established goals. This study was conducted to examine the effects of formalized data assessment and systematic feedback on treatment times. All patients with STEMIs treated with percutaneous coronary intervention in a semirural 3-hospital network from January 1, 2006, to December 31, 2006, were prospectively analyzed (n = 114). Patients presenting during the first 3-month period (January 1, 2006, to March 31, 2006) were included as the reference group (n = 33). Time points from initial contact with the medical system to revascularization were assessed, analyzed, and presented in an interactive session to hospital and emergency services staff members. Data from patients with STEMIs presenting during the next 3 quarters were presented in the same manner (n = 28, 25, and 28). The median contact-to-balloon time was 113 minutes in the reference quarter, decreasing to 83, 66, and 74 minutes in the intervention groups (p <0.0001), whereas the median door-to-balloon time decreased from 54 minutes in the reference group to 35, 31, and 26 minutes in the intervention groups (p <0.0001). The proportion of patients with contact-to-balloon times <90 minutes increased from 21% to 79% (p <0.0001). There were significant reductions in the durations of initial treatment on location and in the emergency room and in puncture-to-balloon-time in the catheterization laboratory, and more patients were transported directly to the catheterization laboratory, bypassing the emergency room (from 23% in the reference quarter to 76% in the last intervention quarter, p <0.0001). In conclusion, formalized data feedback leads to marked reduction in revascularization times in patients with STEMIs. (c) 2008 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.amjcard.2007.07.078"],["dc.identifier.isi","000252136400009"],["dc.identifier.pmid","18157964"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55235"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Excerpta Medica Inc-elsevier Science Inc"],["dc.relation.issn","0002-9149"],["dc.title","Contact-to-balloon time and door-to-balloon time after initiation of a formalized data feedback in patients with acute ST-elevation myocardial infarction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S0304-3959(01)00444-4"],["dc.bibliographiccitation.firstpage","189"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","196"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Leibing, Eric"],["dc.contributor.author","Leonhardt, Urs"],["dc.contributor.author","Köster, Georg"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Rosenfeldt, Joerg-André"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2021-06-01T10:50:15Z"],["dc.date.available","2021-06-01T10:50:15Z"],["dc.date.issued","2002"],["dc.description.abstract","There is some evidence for the efficacy of acupuncture in chronic low-back pain (LBP), but it remains unclear whether acupuncture is superior to placebo. In a randomized. blinded, placebo-controlled trial, we evaluated the effect of traditional acupuncture in chronic LBP. A total of 131 consecutive out-patients of the Department of Orthopaedics, University Goettingen, Germany, (age = 48.1 years, 58.5% female, duration of pain: 9.6 years) with non-radiating LBP for at least 6 months and a normal neurological examination were randomized to one of three groups over 12 weeks. Each group received active physiotherapy over 12 weeks. The control group (n = 46) received no further treatment, the acupuncture group (it = 40) received 20 sessions of traditional acupuncture and the sham-acupuncture group (it = 45) 20 sessions of minimal acupuncture, Changes from baseline to the end of treatment and to 9-month follow-up were assessed in pain intensity and in pain disability, and secondary in psychological distress and in spine flexion, compared by intervention groups. Acupuncture was superior to the control condition (physiotherapy) regarding pain intensity (P = 0.000), pain disability (P = 0.000), and psychological distress (P = 0,020) at the end of treatment. Compared to sham-acupuncture, acupuncture reduced psychological distress (P = 0.040) only. At 9-month follow-up, the superiority of acupuncture compared to the control condition became less and acupuncture was not different to sham-acupuncture. We found a significant improvement by traditional acupuncture in chronic LBP compared to routine care (physiotherapy) but not compared to sham-acupuncture. The trial demonstrated a placebo effect of traditional acupuncture in chronic LBP. (C) 2002 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0304-3959(01)00444-4"],["dc.identifier.isi","000175738800021"],["dc.identifier.pmid","11932074"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86585"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","Acupuncture treatment of chronic low-back pain – a randomized, blinded, placebo-controlled trial with 9-month follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","340"],["dc.bibliographiccitation.issue","05"],["dc.bibliographiccitation.journal","Ultraschall in der Medizin"],["dc.bibliographiccitation.lastpage","344"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Viereck, V."],["dc.contributor.author","Pauer, H. U."],["dc.contributor.author","Bader, W."],["dc.contributor.author","Lange, R."],["dc.contributor.author","Viereck, N."],["dc.contributor.author","Emons, G."],["dc.contributor.author","Hilgers, R."],["dc.contributor.author","Hackenberg, R."],["dc.contributor.author","Krauß, T."],["dc.date.accessioned","2021-06-01T10:51:00Z"],["dc.date.available","2021-06-01T10:51:00Z"],["dc.date.issued","2003"],["dc.identifier.doi","10.1055/s-2003-42911"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86855"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1438-8782"],["dc.relation.issn","0172-4614"],["dc.title","Introitussonographie des unteren Genitaltraktes vor und nach Kolposuspension: eine sechsmonatige Nachbeobachtung"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","485"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Neurourology and Urodynamics"],["dc.bibliographiccitation.lastpage","490"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Kociszewski, Jacek"],["dc.contributor.author","Rautenberg, Oliver"],["dc.contributor.author","Perucchini, Daniele"],["dc.contributor.author","Eberhard, Jakob"],["dc.contributor.author","Geissbuehler, Verena"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Viereck, Volker"],["dc.date.accessioned","2018-11-07T11:20:29Z"],["dc.date.available","2018-11-07T11:20:29Z"],["dc.date.issued","2008"],["dc.description.abstract","Aim: To investigate tension-free vaginal tape (TVT) position and shape using ultrasound (US) and correlate the findings to outcome. Material and Methods: The results of TVT surgery were investigated in 72 women with urodynamic stress urinary incontinence. The main outcome parameters were US tape position in relation to the urethra and dynamic changes in TVT shape at rest and during straining. Results: Sixty-two patients (86%) were continent, 6 (8%) significantly improved, and the operation failed in four cases (6%). The median tape position was at 66% of the urethral length measured by US. The median tape-urethra-lumen distance was 3.8 mm at rest. Tape placement in the upper or lower quarter of the urethra was associated with a higher failure rate. Tapes positioned less than 3 mm from the urethra significantly increased postoperative complications (P < 0.0001). The tape was flat at rest and curved during straining in 44 (61%) patients; 98% (43/44) of these women were continent after surgery. An unchanged tape shape was associated with a poorer outcome (P = 0.00038). Patients with a flat tape at rest and during straining failed in 25% and patients with a permanent curved shape in 10%. Conclusions: TVT position relative to the patient's urethra seems to play a role in treatment outcome. Outcome was best in patients with dynamic change in tape shape during straining and location of the tape at the junction between the lower and middle urethra and at least 3 mm from the urethral lumen."],["dc.identifier.doi","10.1002/nau.20556"],["dc.identifier.isi","000258278500005"],["dc.identifier.pmid","18288705"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55546"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0733-2467"],["dc.title","Tape functionality: Sonographic tape characteristics and outcome after TVT incontinence surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","586"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International Urogynecology Journal"],["dc.bibliographiccitation.lastpage","592"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Pauer, Hans-Ulrich"],["dc.contributor.author","Hesse, Oda"],["dc.contributor.author","Bader, Werner"],["dc.contributor.author","Tunn, Ralf"],["dc.contributor.author","Lange, Rainer"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Emons, Guenter"],["dc.date.accessioned","2018-11-07T09:01:33Z"],["dc.date.available","2018-11-07T09:01:33Z"],["dc.date.issued","2006"],["dc.description.abstract","The aim of this study was to define the concept of hypermobility of the bladder neck and determine its effects on the cure rate and postoperative complications in patients undergoing colposuspension. In a retrospective study, 310 patients who underwent primary colposuspension for urodynamically proven genuine stress urinary incontinence were assessed by introital ultrasound before surgery and during follow-up for up to 48 months postoperatively. A total of 152 women completed 48 months of follow-up. Mobility of the bladder neck during straining was described as linear dorsocaudal movement (LDM) with LDM > 15 mm being defined as hypermobility. The overall objective cure rate was 90.0% at 6-month follow-up vs 76.8% at 48-month follow-up (Kaplan-Meier estimators). Urge symptoms occurred in 12.6% (39/310) of the women and de novo urge incontinence in 2.3% (7/310). Bladder neck hypermobility was significantly reduced after anti-incontinence surgery, from 67.1% (208/310) before surgery to 5.5% (17/310) immediately after surgery (P < 0.0001). Postoperative hypermobility was associated with a higher recurrence rate. In the hypermobility group, 52.9 and 34.0% of the patients were continent for up to 6 and 48 months, respectively, as opposed to 92.2 and 79.2% in the group without hypermobility (P < 0.0001). Women with postoperative hypermobility had a 3.2-fold higher risk of recurrence within 48 months. Bladder neck hypermobility after surgery was also associated with postoperative voiding difficulty (P=0.0278). Patients in whom hypermobility of the bladder neck diagnosed before surgery persists after colposuspension have a higher risk of recurrence and are more likely to develop postoperative complications than those without this hypermobility."],["dc.identifier.doi","10.1007/s00192-006-0071-4"],["dc.identifier.isi","000241259300009"],["dc.identifier.pmid","16538422"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24457"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","London"],["dc.relation.issn","0937-3462"],["dc.title","Urethral hypermobility after anti-incontinence surgery - a prognostic indicator?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","ISRN Pediatrics"],["dc.bibliographiccitation.lastpage","6"],["dc.bibliographiccitation.volume","2012"],["dc.contributor.author","Gross, Oliver"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Görlitz, Anke"],["dc.contributor.author","Gavénis, Karsten"],["dc.contributor.author","Ahmed, Raees"],["dc.contributor.author","Dürr, Ulrike"],["dc.date.accessioned","2019-07-09T11:54:04Z"],["dc.date.available","2019-07-09T11:54:04Z"],["dc.date.issued","2012"],["dc.description.abstract","Introduction. Retrospective observational data show that ACE-inhibitor therapy delays renal failure and improves life expectancy in Alport patients with proteinuria. The EARLY PRO-TECT Alport trial assesses the safety and efficacy of early therapy onset with ramipril in pediatric Alport patients.Methods and analysis. This double-blind, randomized, placebo-controlled, multicenter phase III trial (NCT01485978; EudraCT-number 2010-024300-10) includes 120 pediatric patients aged 24 months to 18 years with early stages of Alport syndrome (isolated hematuria or microalbuminuria). From March 2012, up to 80 patients will be randomized 1:1 to ramipril or placebo. In the event of disease progression during 3-year treatment, patients are unblinded and ramipril is initiated, if applicable. Approximately 40 patients receive open-label ramipril contributing to the safety database. Primary endpoints are “time to progression to next disease level” and “incidence of adverse drug events before disease progression.” Treatment effect estimates from the randomized comparison and Alport registry data will be combined in supportive analyses to maximize evidence. Conclusion. Without this trial, ACE inhibitors may become standard off-label treatment in Alport syndrome without satisfactory evidence base. The results are expected to be of relevance for therapy of all pediatric patients with kidney disease, and the trial protocol might serve as a model for other rare pediatric glomerulopathies."],["dc.identifier.doi","10.5402/2012/436046"],["dc.identifier.fs","587146"],["dc.identifier.pmid","22811928"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8396"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60563"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-4703"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]